Cargando…

Facile total synthesis of lysicamine and the anticancer activities of the Ru(II), Rh(III), Mn(II) and Zn(II) complexes of lysicamine

Lysicamine is a natural oxoaporphine alkaloid, which isolated from traditional Chinese medicine (TCM) herbs and has been shown to possess cytotoxicity to hepatocarcinoma cell lines. Reports on its antitumor activity are scarce because lysicamine occurs in plants at a low content. In this work, we de...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Jiao-Lan, Meng, Ting, Chen, Zhen-Feng, Xie, Xiao-Li, Qin, Qi-Pin, He, Xiao-Ju, Huang, Ke-Bin, Liang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601738/
https://www.ncbi.nlm.nih.gov/pubmed/28938642
http://dx.doi.org/10.18632/oncotarget.19584
_version_ 1783264445400612864
author Qin, Jiao-Lan
Meng, Ting
Chen, Zhen-Feng
Xie, Xiao-Li
Qin, Qi-Pin
He, Xiao-Ju
Huang, Ke-Bin
Liang, Hong
author_facet Qin, Jiao-Lan
Meng, Ting
Chen, Zhen-Feng
Xie, Xiao-Li
Qin, Qi-Pin
He, Xiao-Ju
Huang, Ke-Bin
Liang, Hong
author_sort Qin, Jiao-Lan
collection PubMed
description Lysicamine is a natural oxoaporphine alkaloid, which isolated from traditional Chinese medicine (TCM) herbs and has been shown to possess cytotoxicity to hepatocarcinoma cell lines. Reports on its antitumor activity are scarce because lysicamine occurs in plants at a low content. In this work, we demonstrate a facile concise total synthesis of lysicamine from simple raw materials under mild reaction conditions, and the preparation of the Ru(II), Rh(III), Mn(II) and Zn(II) complexes 1–4 of lysicamine (LY). All the compounds were fully characterized by elemental analysis, IR, ESI-MS, (1)H and (13)C NMR, as well as single-crystal X-ray diffraction analysis. Compared with the free ligand LY, complexes 2 and 3 exhibited superior in vitro cytotoxicity against HepG2 and NCI-H460. Mechanistic studies indicated that 2 and 3 blocked the cell cycle in the S phase by decreasing of cyclins A2/B1/D1/E1, CDK 2/6, and PCNA levels and increasing levels of p21, p27, p53 and CDC25A proteins. In addition, 2 and 3 induced cell apoptosis via both the caspase-dependent mitochondrial pathway and the death receptor pathway. in vivo study showed that 2 inhibited HepG2 tumor growth at 1/3 maximum tolerated dose (MTD) and had a better safety profile than cisplatin.
format Online
Article
Text
id pubmed-5601738
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56017382017-09-21 Facile total synthesis of lysicamine and the anticancer activities of the Ru(II), Rh(III), Mn(II) and Zn(II) complexes of lysicamine Qin, Jiao-Lan Meng, Ting Chen, Zhen-Feng Xie, Xiao-Li Qin, Qi-Pin He, Xiao-Ju Huang, Ke-Bin Liang, Hong Oncotarget Research Paper Lysicamine is a natural oxoaporphine alkaloid, which isolated from traditional Chinese medicine (TCM) herbs and has been shown to possess cytotoxicity to hepatocarcinoma cell lines. Reports on its antitumor activity are scarce because lysicamine occurs in plants at a low content. In this work, we demonstrate a facile concise total synthesis of lysicamine from simple raw materials under mild reaction conditions, and the preparation of the Ru(II), Rh(III), Mn(II) and Zn(II) complexes 1–4 of lysicamine (LY). All the compounds were fully characterized by elemental analysis, IR, ESI-MS, (1)H and (13)C NMR, as well as single-crystal X-ray diffraction analysis. Compared with the free ligand LY, complexes 2 and 3 exhibited superior in vitro cytotoxicity against HepG2 and NCI-H460. Mechanistic studies indicated that 2 and 3 blocked the cell cycle in the S phase by decreasing of cyclins A2/B1/D1/E1, CDK 2/6, and PCNA levels and increasing levels of p21, p27, p53 and CDC25A proteins. In addition, 2 and 3 induced cell apoptosis via both the caspase-dependent mitochondrial pathway and the death receptor pathway. in vivo study showed that 2 inhibited HepG2 tumor growth at 1/3 maximum tolerated dose (MTD) and had a better safety profile than cisplatin. Impact Journals LLC 2017-07-26 /pmc/articles/PMC5601738/ /pubmed/28938642 http://dx.doi.org/10.18632/oncotarget.19584 Text en Copyright: © 2017 Qin et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Qin, Jiao-Lan
Meng, Ting
Chen, Zhen-Feng
Xie, Xiao-Li
Qin, Qi-Pin
He, Xiao-Ju
Huang, Ke-Bin
Liang, Hong
Facile total synthesis of lysicamine and the anticancer activities of the Ru(II), Rh(III), Mn(II) and Zn(II) complexes of lysicamine
title Facile total synthesis of lysicamine and the anticancer activities of the Ru(II), Rh(III), Mn(II) and Zn(II) complexes of lysicamine
title_full Facile total synthesis of lysicamine and the anticancer activities of the Ru(II), Rh(III), Mn(II) and Zn(II) complexes of lysicamine
title_fullStr Facile total synthesis of lysicamine and the anticancer activities of the Ru(II), Rh(III), Mn(II) and Zn(II) complexes of lysicamine
title_full_unstemmed Facile total synthesis of lysicamine and the anticancer activities of the Ru(II), Rh(III), Mn(II) and Zn(II) complexes of lysicamine
title_short Facile total synthesis of lysicamine and the anticancer activities of the Ru(II), Rh(III), Mn(II) and Zn(II) complexes of lysicamine
title_sort facile total synthesis of lysicamine and the anticancer activities of the ru(ii), rh(iii), mn(ii) and zn(ii) complexes of lysicamine
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601738/
https://www.ncbi.nlm.nih.gov/pubmed/28938642
http://dx.doi.org/10.18632/oncotarget.19584
work_keys_str_mv AT qinjiaolan faciletotalsynthesisoflysicamineandtheanticanceractivitiesoftheruiirhiiimniiandzniicomplexesoflysicamine
AT mengting faciletotalsynthesisoflysicamineandtheanticanceractivitiesoftheruiirhiiimniiandzniicomplexesoflysicamine
AT chenzhenfeng faciletotalsynthesisoflysicamineandtheanticanceractivitiesoftheruiirhiiimniiandzniicomplexesoflysicamine
AT xiexiaoli faciletotalsynthesisoflysicamineandtheanticanceractivitiesoftheruiirhiiimniiandzniicomplexesoflysicamine
AT qinqipin faciletotalsynthesisoflysicamineandtheanticanceractivitiesoftheruiirhiiimniiandzniicomplexesoflysicamine
AT hexiaoju faciletotalsynthesisoflysicamineandtheanticanceractivitiesoftheruiirhiiimniiandzniicomplexesoflysicamine
AT huangkebin faciletotalsynthesisoflysicamineandtheanticanceractivitiesoftheruiirhiiimniiandzniicomplexesoflysicamine
AT lianghong faciletotalsynthesisoflysicamineandtheanticanceractivitiesoftheruiirhiiimniiandzniicomplexesoflysicamine